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Choice of therapy: Patients should be treated with the
most potent antiviral agent available. This is to ensure
maximal suppression of viral replication. A viral load of less
than about 50,000 copies is usually sufﬁcient to prevent
progression of disease. However, in order to prevent the
development of antiviral resistance the target viral load
should be undetectable. Using lamivudine or telbivudine
viral loads greater than about 200 copies/ml 6 months
after starting treatment indicates inadequate response, and
should be a reason to change treatment. With the more
potent agents this is less important.
Duration of therapy: Patients who are positive for HBeAg
should be treated until 6 12 months after seroconversion.
However, since remission may not be durable these
patients should be monitored indeﬁnitely after stopping
therapy. Patients who are anti-HBe-positive need treatment
indeﬁnitely
Combination therapy: As yet there is no data on the use
of combination therapy as ﬁrst line treatment. Possible
combinations include one of lamivudine, telbivudine, or
entecavir with either adefovir or tenofovir. Lamivudine
telbivudine and entecavir should not be used together.
Tenofovir and adefovir should not be used together. Truvada
is the combination of emtricitabine and tenofovir in a single
tablet. Emtricitabine is very similar to lamivudine.
Treatment of antiviral resistance: Patients should be
monitored frequently so that if resistance develops it can
be caught early. Early treatment of antiviral resistance is
more effective than treating resistance one ALT elevation
has occurred. Resistance is deﬁned as more than a 1 log
increase in viral load assuming good compliance.
Resistance to lamivudine or telbivudine is treated
conventionally by adding adefovir. Addition of a second
drug is more effective that switching to a second drug.
Adefovir, but tenofovir will probably be a better choice in
future. It is not known whether tenofovir will require to be
used in combination or not. Since patients who develop
antiviral resistance to more than one agent have very
few if any further options and argument can be made for
treating these patients with a combination of tenofovir and
entecavir. Resistance to entecavir is treated with adefovir
or tenofovir. Resistance to adefovir or tenofovir should be
treated with entecavir.
Long term monitoring: Patients with chronic hepatitis B
should undergo 6 monthly ultrasound screening for HCC.
Patients with known cirrhosis should also have a gastroscopy
to look for esophageal varices.
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Background and Aim: Chronic hepatitis B (CHB) is
thought to involve aberrant immune tolerance of unknown
mechanism. In this study, the immune modulatory effect of
adefovir dipivoxil (ADV) and Entecavir (ETV) was determined
in CHB patients who are positive for hepatitis B e antigen
(HBeAg) based on the efﬁcacy and safety of the Phase IV,
randomized controlled trial result.
Methods: 56 CHB patients were treated with ADV or ETV
and 24 healthy subjects were used as a control. Two classes
of cytokines including IL-2, IFN-g, TNF-a, IL-4, IL-6, IL-10
and regulatory T cells (Tregs), CD4 and CD8 were measured
before treatment and at 12, 24, 36 and 48 weeks after
treatment using a three-color ﬂow cytometry. Samples were
also tested for HBVDNA, ALT and AST.
Results: In patients treated with ADV or ETV, both Th1
and Th2 cytokines were signiﬁcantly increased and found
to be higher than the controls (p < 0.01). The cytokines
production was continuously increased along with treatment
from weeks 12 up to 48. After 24 weeks of treatment,
HBVDNA was greatly reduced among ETV compared to ADV
treatment (p < 0.05), and high production of IL-2, IFN-g,
TNF-a were observed with ETV compared to ADV treatment.
The IFN-g level at weeks 24 and 48 among patients treated
with ETV (16.74±1.34%, 19.78±1.56%) were signiﬁcantly
higher than ADV (7.53±0.55%, 12.56±0.89%) (P< 0.005).
The IL-2 level at weeks 24 and 48 among patients treated
with ETV (10.62±1.11%, 13.14±1.06%) were signiﬁcantly
higher than ADV (5.84±0.46%, 9.46±0.79%) (P< 0.05). The
TNF-a levels at weeks 24 and 48 among patients treated
with ETV (18.35±2.74%, 17.32±1.63%) were signiﬁcantly
higher than ADV (9.96±0.87%, 12.32±1.22%) (P< 0.05). Both
the proportion of CD4+CD25high Tregs (3.08%±0.38%) and
CD4+CD25+CD127low/ Tregs (9.05%±0.69%) were showed
a statistically signiﬁcant increase compared to healthy
controls (1.60%±0.66%, p < 0.01), (1.92%±0.16%, p < 0.01).
The Tregs decreased among patients treated with both
nucleot(s)ide analogue after week 12 until the 36 week.
The CD4/CD8 ratio and the percent of CD4 in CHB
were both signiﬁcantly higher than controls (p < 0.001) and
the CD4/CD8 ratio were showed a statistically signiﬁcant
decrease compared to the baseline after 24 weeks. IL-6,
IL-10, Tregs and the percent of CD4 were associated with
HBVDNA levels at week 24, but were independently related
to ALT and AST level.
Conclusion: Antiviral therapy with ADV or ETV can increase
the Th1/Th2 cytokine secretion in patients with chronic
hepatitis B. ETV induced the secretion of IFN-g more than
ADV. The proportion of Tregs decreased after treatment
of nucleot(s)ide analogue. Cytokine and Treg play an active
role not only in modulating effectors of immune response to
HBV infection, but also in inﬂuencing the disease prognosis
in patients with hepatitis B.
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The major limitation of long-term antiviral therapy for
chronic hepatitis B is the emergence of drug resistance
which negates the beneﬁts of therapy. To minimize the
chance of emergence of hepatitis B virus with drug
resistance, antiviral agent(s) with rapid and potent viral
suppression and high genetic barrier should be the
treatment of choice. If an antiviral agent not possessing
these properties is used, early measurement of HBVDNA
levels should be performed to guide the treatment plan in
the subsequent course. Measurement of viral load reduction
at 24 weeks of treatment to aid decision making should be
mandatory for patients who are receiving antiviral agents
with low genetic barrier. Combination therapy for treatment
naı¨ve patients using two antiviral agents belonging to
different groups is associated with a lower chance of
emergence of drug resistance. However, the best choice
of combination therapy associated with an acceptable low
chance of drug resistance is still being eagerly awaited. With
the availability of various antiviral agents from different
groups, drug resistant HBV to a particular antiviral agent
usually remains susceptible to another antiviral agent of
different group. To ensure better control of viral replication
in patients with drug resistance, adding on or switching
to another antiviral agent with no overlapping resistance
proﬁle should be administered as early as possible, e.g. at
the time when genotypic resistance emerges.
